Cardiovascular diseases in pregnancy: the most important messages of the new guidelines

    Authors

    Abstract

    A review of the key points of the new European Society of Cardiology (ESC) guidelines for the treatment of cardiovascular disease during pregnancy. (1) The new ESC guidelines for the treatment of cardiovascular disease during pregnancy recommend the modified World Health Organization classification of maternal risk. In pharmacological therapy, decision making based on Food and Drug Administration (FDA) drugs in pregnancy categories A-X is no longer recommended. There are also changes in antiarrhythmic therapy as well as anticoagulation and thrombolytic therapy during pregnancy. Changes were made regarding timing of intervention in valvular disease and also in diagnostics of deep vein thrombosis in pregnant women. A few changes have been made regarding the management of hypertension and the pregnancy heart team is introduced.

    Keywords

    cardiovascular diseases, pregnancy, guidelines

    DOI

    https://doi.org/10.15836/ccar2018.384

    Literature

    1. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165–241. https://doi.org/10.1093/eurheartj/ehy340
    Cardiologia Croatica
    Back to search

    Cardiovascular diseases in pregnancy: the most important messages of the new guidelines

    Extended Abstract
    Issue11-12
    Published
    Pages384
    PDF via DOIhttps://doi.org/10.15836/ccar2018.384
    cardiovascular diseases
    pregnancy
    guidelines

    Authors

    Diana Delić-Brkljačić*ORCIDKlinički bolnički centar Sestre milosrdnice, Zagreb, Hrvatska

    *Correspondence email: diana.delic.brkljacic@kbcsm.hr

    Abstract

    A review of the key points of the new European Society of Cardiology (ESC) guidelines for the treatment of cardiovascular disease during pregnancy. (1) The new ESC guidelines for the treatment of cardiovascular disease during pregnancy recommend the modified World Health Organization classification of maternal risk. In pharmacological therapy, decision making based on Food and Drug Administration (FDA) drugs in pregnancy categories A-X is no longer recommended. There are also changes in antiarrhythmic therapy as well as anticoagulation and thrombolytic therapy during pregnancy. Changes were made regarding timing of intervention in valvular disease and also in diagnostics of deep vein thrombosis in pregnant women. A few changes have been made regarding the management of hypertension and the pregnancy heart team is introduced.

    Literature

    1. 1.
      Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165–241.DOI